C E N T E R F O R V A C C I N E I N N O V A T I O N A N D A C C E S S

MAILING ADDRESS PO Box 900922

Seattle, WA 98109 USA

PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve

health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs,

diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public

health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale,

working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver

measurable results that disrupt the cycle of poor health. Learn more at www.path.org.

STREET ADDRESS 2201 Westlake Avenue

Suite 200

Seattle, WA 98121 USA

www.path.org

March 2017

Saving lives through immunization

For more than 20 years, PATH has successfully developed and delivered lifesaving vaccines for the most vulnerable children and communities around the world, spanning the spectrum of discovery to development to delivery. PATH established the Center for Vaccine Innovation and Access (CVIA) in 2016 to strengthen, accelerate, and coordinate this broad range of work—from preclinical research on novel candidates through pivotal clinical evaluations and, ultimately, innovative approaches for new vaccine introduction and access.

CVIA’s current portfolio encompasses more than two dozen vaccines either in development or already in use to protect against 17 different diseases. By bringing together diverse experience and expertise in both disease and functional areas (see Figure 1) and sharing lessons learned across a variety of projects, CVIA is able to be more agile and flexible as global health challenges emerge and deliver vaccines with optimal public health impact for children, families, and communities most in need.

ADVANCING DEVELOPMENT

CVIA’s vaccine development efforts focus on the leading causes of child deaths worldwide—pneumonia, diarrheal diseases, and malaria—as well as other global health priorities, such as polio and meningitis. CVIA works in partnership with communities, national health ministries, donors, international financing and regulatory organizations, vaccine manufacturers—particularly those in developing countries—and many others to diligently design, develop, and improve new vaccines that are safe, effective, affordable, and acceptable in the communities that need them most. PATH has led numerous global partnerships, including the award-winning Meningitis Vaccine Project and the Malaria Vaccine Initiative, which partnered with GSK in developing the first malaria vaccine candidate recommended for pilot implementation.

Figure 1. CVIA applies its experience and expertise on every aspect of vaccine development and introduction across its broad portfolio. For more

information, visit http://sites.path.org/cvia/.

ENSURING ACCESS

CVIA works with multiple partners in low-resource settings to ensure that safe and effective vaccines are accessible to those who need them in as little time as possible. For example, one CVIA team led an effort to turn a little-known Japanese encephalitis vaccine from China into an internationally approved tool that has been delivered to over 230 million people in six high-burden countries. To help guide country decision-makers on vaccine introductions, CVIA generates and disseminates new evidence on vaccine delivery strategies, supply and demand, and cost-effectiveness. Working with policy agencies such as the World Health Organization and financing bodies such as Gavi, the Vaccine Alliance, CVIA helps shape global efforts that prioritize vaccine introduction and sustain strong delivery systems. CVIA also works closely with national governments to communicate the value of vaccines and ensure critical financial, political, and community support.

PATH’s Center for Vaccine Innovation and Access (CVIA) accelerates access to vaccines through innovation across the discovery, development, and delivery spectrum.